Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Breast Cancer
Interventions
DRUG

Docetaxel

Docetaxel at the dose of 75mg/m\^2 IV on day 1 every 3 weeks for 6 consecutive cycles

DRUG

Carboplatin

Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles

DRUG

Herceptin

Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks

DRUG

Vinorelbine

Vinorelbine at the dose of 60mg/m\^2 per os,weekly

Trial Locations (10)

71110

University Hospital of Crete, Heraklion

Unknown

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

401 Military Hospital of Athens, Athens

Air Forces Military Hospital of Athens, Athens

"Marika Iliadis Hospital of Athens, Dep of Medical Oncology", Athens

State General Hospital of Larissa, Athens

"Metaxa's Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology", Piraeus

"Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology", Thessaloniki

All Listed Sponsors
collaborator

University Hospital of Crete

OTHER

lead

Hellenic Oncology Research Group

OTHER